Related Experiment Video
Updated: Sep 11, 2025
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Variations in Circulating Tumor Microenvironment-Associated Proteins in Non-Muscle Invasive Bladder Cancer Induced by
Benito Blanco Gómez1, Francisco Javier Casas-Nebra1, Daniel Pérez-Fentes2
1Urology Division, Lucus Augusti University Hospital (HULA), Servizo Galego de Saúde (SERGAS), 27002 Lugo, Spain.
Abstract:
Mitomycin C (MMC) is a widely employed chemotherapeutic agent, particularly in non-muscle invasive bladder cancer (NMIBC), where it functions by inducing DNA cross-linking and promoting tumor cell apoptosis. However, the tumor microenvironment (TME) significantly influences the therapeutic efficacy of MMC. Among the key regulators within the TME, the complement system and the coagulation pathway play a crucial role in modulating immune responses to cancer therapies, including MMC. This article explores the interaction between platinum nanoparticles (PtNPs) with human serum (HS) of NMIBC patients (T1 and Ta subtypes) at three different points: before the chemotherapy instillation of MMC (t0) and three (t3) and six months (t6) after the treatment with MMC. This novel nanoproteomic strategy allowed the identification of a TME proteomic signature associated with the response to MMC treatment. Importantly, two proteins involved in the immune response were found to be deregulated across all patients (T1 and Ta subtypes) during MMC treatment: prothrombin (F2) downregulated and complement component C7 (C7) upregulated. By understanding how these biomarker proteins interact with MMC treatment, novel therapeutic strategies can be developed to enhance treatment outcomes and overcome resistance in NMIBC.
Insights
This study identifies key protein changes in the tumor microenvironment during Mitomycin C (MMC) treatment for bladder cancer. Prothrombin and complement component C7 levels shift, offering insights into treatment response and resistance.
Area of Science:
- Oncology
- Proteomics
- Immunology
Background:
- Mitomycin C (MMC) is a chemotherapy for non-muscle invasive bladder cancer (NMIBC).
- The tumor microenvironment (TME) influences MMC efficacy, with complement and coagulation pathways being key regulators.
- Understanding TME-drug interactions is crucial for improving NMIBC treatment.
Purpose of the Study:
- To explore platinum nanoparticles (PtNPs) interaction with human serum (HS) from NMIBC patients.
- To identify a TME proteomic signature linked to MMC treatment response.
- To investigate changes in key immune-related proteins during MMC therapy.
Main Methods:
- Nanoproteomic strategy applied to HS from NMIBC patients (T1 and Ta subtypes).
- Serum samples collected at baseline (t0), 3 months (t3), and 6 months (t6) post-MMC treatment.
- Analysis focused on protein deregulation associated with MMC therapy.
Main Results:
- Identified a TME proteomic signature associated with MMC treatment response.
- Prothrombin (F2) was consistently downregulated across all patients.
- Complement component C7 (C7) was consistently upregulated across all patients.
Conclusions:
- Prothrombin and C7 are potential biomarkers for MMC treatment response in NMIBC.
- Understanding these protein dynamics can inform new therapeutic strategies.
- This research may help overcome MMC resistance and improve patient outcomes.
